Indications/Uses

Hypertension: Treatment of essential hypertension in adults.
Cardiovascular prevention: Reduction of cardiovascular morbidity in adults with manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage.

Dosage/Direction for Use

Hypertension: Usual starting dose: 40 mg once a day.
Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks.
When additional blood pressure reduction beyond that achieved with 80 mg telmisartan is required, a diuretic may be added.
No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
Cardiovascular risk reduction: Recommended dose: 80 mg once a day.
It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality.
When initiating telmisartan therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.
Telmisartan tablets may be administered with other antihypertensive agents. Telmisartan tablets may be administered with or without food.

Administration

May be taken with or without food.

Contraindications

Second and third trimesters of pregnancy.
Biliary obstructive disorders.
Severe hepatic impairment.
Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73m²).

Special Precautions

Dual blockade of RAAS through combination w/ ACE inhibitors or aliskiren is not recommended. Not to be used concomitantly w/ ACE inhibitors in patients w/ diabetic nephropathy. Not recommended in patients w/ primary aldosteronism. Increased risk of severe hypotension & renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Hyperkalemia. Patients w/ aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy; severe CHF or underlying renal disease including renal artery stenosis; ischemic cardiopathy or CV disease. Correct symptomatic hypotension prior to administration in patients who are vol &/or Na depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting. Periodically monitor K & creatinine serum levels in patients w/ renal impairment. Not recommended during pregnancy (1st trimester) & lactation.

Storage

Store at temperatures not exceeding 30°C.

MedsGo Class

Angiotensin II Antagonists

TELMIGEN Telmisartan 40mg Tablet 1's